K.J. Harrison & Partners Inc lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 53.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,861 shares of the company's stock after selling 9,000 shares during the quarter. K.J. Harrison & Partners Inc's holdings in Johnson & Johnson were worth $1,304,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth about $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
JNJ has been the topic of several analyst reports. Raymond James Financial decreased their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
NYSE JNJ traded up $0.34 during trading hours on Friday, reaching $155.90. The company's stock had a trading volume of 3,482,521 shares, compared to its average volume of 8,047,072. The stock has a market cap of $375.11 billion, a PE ratio of 17.34, a PEG ratio of 2.36 and a beta of 0.41. The business has a 50-day simple moving average of $153.65 and a 200 day simple moving average of $153.96. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.34%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is presently 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
